Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: A vehicle includes a frame, an implement, and an outrigger. The implement is coupled with the frame. The implement is configured to be operated to move or lift another vehicle. The outrigger assembly is fixedly coupled with the vehicle. The outrigger assembly includes a member and a foot assembly. The foot assembly is coupled with an end of the member. The member is repositionable to drive the foot assembly into contact with a ground surface. The foot assembly includes a first plate and a second plate defining multiple edges configured to engage the ground surface. The first plate and the second plate are rotatably repositionable in unison about a first axis between multiple positions. The second plate is, relative to the first plate, rotatably repositionable about a second axis that is perpendicular with the first axis.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: A method includes receiving, from a computing device, a request for content from a content provider and determining one or more experiment variations of the requested content that the computing device is assigned to based, at least in part, on the request. The method further includes generating, by a processing device, code indicating the determined one or more experiment variations and inserting the code into executable code corresponding to the requested content. The executable code is transmitted to the browser.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: A method includes receiving, from a computing device, a request for content hosted by a content provider and determining one or more experiment variations for the requested content that the computing device is assigned to based, at least in part, on the request. The method further includes generating, by a processing device, a hash value of the one or more experiment variations and transmitting the hash value to the computing device and to a caching server.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: A mobility management system receives movement data from sensors that detect movements of a patient resting in a patient support apparatus and movement data from one or more mobility detection devices that detect movement of the patient when the patient exits the patient support apparatus. The system determines a mobility status based on at least the movement data received from the patient support apparatus and the one or more mobility detection devices, and adjusts a care protocol for the patient based on the mobility status.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.